Work

Baseline Characteristics and Interim Safety in RESPOND: A Phase 4 Study in Children with Spinal Muscular Atrophy (SMA) Treated With Nusinersen After Onasemnogene Abeparvovec (P7-9.003)

Year: 2023

Type: article

Study design: Clinical Trial

Source: Neurology

DOI: 10.1212/wnl.0000000000203152

Authors: Nancy Kuntz, Julie Parsons, John F. Brandsema, Crystal Proud, Richard Finkel, Kathryn Swoboda, Ricardo Masson, Yingying Liu, Corinne Makepeace, Angela Paradis, Zdenek Berger, Kathleen Somera-Molina

Institutions: Lurie Children's Hospital, Children's Hospital Colorado, Children's Hospital of Philadelphia, Children's Hospital of The King's Daughters, St. Jude Children's Research Hospital, Massachusetts General Hospital, Fondazione IRCCS Istituto Neurologico Carlo Besta, Biogen (United States)

Language: English

Topic: Neurogenetic and Muscular Disorders Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367303162

FWCI: 0.173

Cites:

Cited by: 1

Related to: 10